Jessica Hergert

The update is in agreement with the FDA approval of a labeling supplement in June 2021 to the United States Prescribing Information for neratinib in HER2-positive breast cancer.

Checkpoint inhibitors may have clinical utility in BTC based on immunogenic features of the disease; however, limited clinical activity has been observed with single-agent therapy in the advanced setting.

Event co-chair, Syma Iqbal, MD, discusses key points from a recent OncLive® Institutional Perspectives in Cancer webinar, which focused on the evolving landscapes in gastrointestinal cancer.

Nuanced and multidisciplinary decision making are needed to optimize and personalize locoregional, systemic, and supportive care in metastatic breast cancer.

The COVID-19 pandemic has demonstrated that personalized medicine should consider social determinants of health disparities as well as genomic factors.

The increased risk of prostate cancer associated with MSH2 and MSH6 pathogenic variants point to a need for annual PSA screening in men over the age of 40.

CAR T-cell therapies represent a potent treatment option for patients with heavily pretreated relapsed/refractory hematologic malignancies, however, the infection risk associated with treatment may hinder the efficacy of COVID-19 vaccines in this population.

Ruxolitinib and belumosudil represent FDA-approved treatment options to manage cGVHD, however, real world data will determine best practices for treatment and future research directions within the space.

Antoinette Wozniak, MD, FACP, FASCO, outlines the importance of careful patient monitoring in lung cancer and emerging therapy options expected to change the treatment landscape.

The recently launched phase 2 ACE-Breast03 seeks to appraise the efficacy and safety of the novel antibody-drug conjugate, ARX788, in patients with metastatic HER2-positive breast cancer whose disease is resistant to previous targeted therapies.

Combining immunotherapy with other targeted therapies may result in more promising outcomes than immunotherapy alone in the treatment of recurrent ovarian cancer, according to an expert at University of California, Los Angeles.

An expert from The University of Texas MD Anderson Cancer Center recently highlighted the ramifications of the phase 2 ReDOS trial, the need for molecular profiling in mCRC, and ongoing research on the combination of TKIs and checkpoint inhibitors.

“I think the biggest [change] that we’ve seen is the addition of adjuvant or consolidated chemotherapy following the completion of concurrent chemotherapy and radiation. We have seen the 4-year overall survival data now and the 5-year update from the PACIFIC study in the adjuvant setting, obviously confirming the initial signal that patients who have initiation of immunotherapy early carry a significant risk reduction for progression and overall survival…”

The prognostic value of minimal residual disease negativity in multiple myeloma may make it a suitable surrogate endpoint in clinical trials, according to a group of researchers.

Early lines of treatment for non-small cell lung cancer treatment might be effectively guided by minimal residual disease.

Study results have posited plinabulin as a potentially effective preventative and active therapy due to its unique mechanism of action.

The impact of the pandemic in regard to specialty care remains to be fully realized.

A presentation from the 2021 ASCO Annual Meeting highlights the current limitations of Cabozantinib as a treatment for RCC.

While merkel cell carcinoma (MCC) tends to have poor prognoses and limited treatment options, promising response rates with checkpoint inhibitors may pave the way for better treatment for the rare skin cancer.

While cabozantinib exposure was not a predictor of progression-free survival, it was related to high rate of palmar-plantar plantar erythrodysesthesia and diarrhea in patients with advanced renal cell carcinoma who are given frontline cabozantinib plus nivolumab.

Comprehensive geriatric assessment can identify age-related vulnerabilities, determine patient fitness, and confirm physiological age through multidisciplinary evaluations of multiple health domains.

Public health efforts must address new methods of cancer screening, an expert says.

Ultimately, the goal is for every eligible patient to receive PARP inhibition in the frontline maintenance setting alone or in combination with bevacizumab, one expert says.

BCMA-directed CAR T-cell therapy is drastically changing the multiple myeloma treatment landscape.

Multidisciplinary care is key to improve quality of life, lessen cancer-related complications, and improve outcomes for patients with pancreatic cancer.

Tanya Dorff, MD, discusses how the FDA approvals of olaparib and rucaparib have paved the way for additional research with PARP inhibitors in metastatic castration-resistant prostate cancer.

Mendel Goldfinger, MD, discusses some of the key points of the ECHELON-1 trial data.

Optimizing first- and second-line therapy, understanding the role of maintenance therapy for patients with BRCA-positive disease, and developing improved therapeutic options for elderly patients has become a priority for research in metastatic pancreatic cancer.

Mehrdad Abedi, MD, discusses the challenges of standard transplant, how Orca-T could overcome some of those limitations, and the potential future of transplant in hematologic malignancies.

A simplified geriatric assessment offers a validated objective tool to assess fitness status and should be considered the new Elderly Prognostic Index standard to predict overall survival in older patients with diffuse large B-cell lymphoma.